ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by AQR Capital Management LLC

AQR Capital Management LLC lessened its stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) by 14.4% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 12,241 shares of the company’s stock after selling 2,057 shares during the quarter. AQR Capital Management LLC’s holdings in ORIC Pharmaceuticals were worth $87,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of ORIC. Vanguard Group Inc. increased its stake in shares of ORIC Pharmaceuticals by 27.9% in the 1st quarter. Vanguard Group Inc. now owns 2,882,055 shares of the company’s stock valued at $39,628,000 after purchasing an additional 629,536 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of ORIC Pharmaceuticals by 140.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,566,736 shares of the company’s stock valued at $21,543,000 after purchasing an additional 915,175 shares in the last quarter. First Turn Management LLC increased its stake in shares of ORIC Pharmaceuticals by 38.1% in the 2nd quarter. First Turn Management LLC now owns 1,515,960 shares of the company’s stock valued at $10,718,000 after purchasing an additional 418,389 shares in the last quarter. NEA Management Company LLC purchased a new position in shares of ORIC Pharmaceuticals in the 1st quarter valued at about $20,625,000. Finally, Dimensional Fund Advisors LP increased its stake in shares of ORIC Pharmaceuticals by 190.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 466,662 shares of the company’s stock valued at $3,299,000 after purchasing an additional 305,860 shares in the last quarter. Institutional investors and hedge funds own 95.05% of the company’s stock.

ORIC Pharmaceuticals Stock Up 3.3 %

NASDAQ:ORIC opened at $9.45 on Friday. The stock’s fifty day moving average is $9.87 and its two-hundred day moving average is $9.38. ORIC Pharmaceuticals, Inc. has a 52 week low of $5.34 and a 52 week high of $16.65. The stock has a market capitalization of $666.60 million, a price-to-earnings ratio of -5.40 and a beta of 1.12.

ORIC Pharmaceuticals (NASDAQ:ORIC) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.03). On average, sell-side analysts expect that ORIC Pharmaceuticals, Inc. will post -1.8 EPS for the current fiscal year.

Analyst Ratings Changes

ORIC has been the subject of several recent analyst reports. Wedbush restated an “outperform” rating and issued a $20.00 price target on shares of ORIC Pharmaceuticals in a research note on Tuesday, September 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of ORIC Pharmaceuticals in a research note on Monday, September 23rd. Oppenheimer cut their price objective on ORIC Pharmaceuticals from $17.00 to $15.00 and set an “outperform” rating for the company in a research note on Tuesday, August 13th. Stifel Nicolaus began coverage on ORIC Pharmaceuticals in a research note on Friday, September 6th. They set a “buy” rating and a $20.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $21.00 price objective on shares of ORIC Pharmaceuticals in a research note on Wednesday, September 18th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, ORIC Pharmaceuticals has an average rating of “Buy” and an average target price of $18.00.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.